Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Focal Segmental Glomerulosclerosis”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Testing effectiveness (Phase 2)Ended earlyNCT05441826
What this trial is testing

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Minimal Change DiseaseFocal Segmental Glomerulosclerosis
Tenet Medicines 1
Post-approval studies (Phase 4)Study completedNCT02633046
What this trial is testing

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

Who this might be right for
Idiopathic Focal Segmental Glomerulosclerosis
Mallinckrodt ARD LLC 63
Large-scale testing (Phase 3)Looking for participantsNCT07220083
What this trial is testing

Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Focal Segmental Glomerulosclerosis
Boehringer Ingelheim 286
Testing effectiveness (Phase 2)Looking for participantsNCT06466135
What this trial is testing

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Who this might be right for
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences 96
Not applicableLooking for participantsNCT04065438
What this trial is testing

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

Who this might be right for
Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC 35
Early research (Phase 1)Study completedNCT00464321
What this trial is testing

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Who this might be right for
Focal Segmental Glomerulosclerosis
Genzyme, a Sanofi Company 16
Testing effectiveness (Phase 2)Study completedNCT00814255
What this trial is testing

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Who this might be right for
Focal Segmental Glomerulosclerosis
NYU Langone Health 32
Not applicableLooking for participantsNCT06065852
What this trial is testing

National Registry of Rare Kidney Diseases

Who this might be right for
Adenine Phosphoribosyltransferase DeficiencyAH AmyloidosisAHL Amyloidosis+81 more
UK Kidney Association 35,000
Testing effectiveness (Phase 2)Looking for participantsNCT06500702
What this trial is testing

Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi 84
Testing effectiveness (Phase 2)WithdrawnNCT00550342
What this trial is testing

Rituximab Treatment of Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Segmental Glomerulosclerosis (FSGS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Early research (Phase 1)Study completedNCT05314231
What this trial is testing

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Who this might be right for
Proteinuria
Alexion Pharmaceuticals, Inc. 13
Large-scale testing (Phase 3)Study completedNCT03493685
What this trial is testing

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. 371
Testing effectiveness (Phase 2)Study completedNCT01665391
What this trial is testing

Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Genzyme, a Sanofi Company 36
Testing effectiveness (Phase 2)Study completedNCT02000440
What this trial is testing

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Glomerulosclerosis, Focal Segmental
GlaxoSmithKline 17
Testing effectiveness (Phase 2)Study completedNCT01613118
What this trial is testing

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. 109
Not applicableStudy completedNCT04369183
What this trial is testing

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisMinimal Change Disease
Istanbul University 25
Testing effectiveness (Phase 2)Study completedNCT04983888
What this trial is testing

Obinutuzumab in Primary FSGS

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Mayo Clinic 20
Testing effectiveness (Phase 2)Looking for participantsNCT06664814
What this trial is testing

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI) 30
Testing effectiveness (Phase 2)Study completedNCT03649152
What this trial is testing

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

Who this might be right for
Focal Segmental Glomerulosclerosis
Dimerix Bioscience Pty Ltd 8
Not applicableWithdrawnNCT00302536
What this trial is testing

Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Glomerulosclerosis
Nanjing University School of Medicine
Load More Results